Moderna is counting on revenue from newer mRNA vaccines, including a next generation Covid shot, to make up for falling sales.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
UnitedHealth Group has called in its CEO to deal with a Medicare Advantage program that’s crunching margins.
The Trump administration promised to drastically cut prescription drugs prices in the US, where the industry makes most of its money.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
US President Donald Trump is reportedly considering linking prescription drug prices to their price tags in other developed nations.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.
Though Isomorphic is burning through millions in R&D costs now, investors have high hopes for the potential of AI drug development.
Novo Nordisk will sell its blockbuster weight-loss drug Wegovy for under half its normal price via a new direct-to-consumer online pharmacy.
Eli Lilly last week announced a $27 billion investment in four different domestic manufacturing plants to boost weight-loss drug production.
Now that semaglutide’s no longer in shortage territory, the FDA said drug-makers have 90 days to wrap up production of their Novo knockoffs.
It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.
Pharma giant Merck on Tuesday announced in its earnings report that it would halt all shipments of HPV drug Gardasil to China.
Tech firms are seeking patents for AI-powered medical devices.
Americans make about 150 million trips to emergency departments each year. Their bank accounts wish they made far fewer.
Behind the blinding white light of Monday’s trillion–dollar AI wipeout that was a spot of unabashedly good AI news.
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.